Search for: "Federal, Inc." Results 61 - 80 of 57,594
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
27 Nov 2023, 9:10 pm by Patent Docs
Noonan -- The Federal Circuit dismissed an appeal from an unsuccessful challenger in an inter partes review (IPR) proceeding based on failure to satisfy the standing requirements for appeal in Allgenesis Biotherapeutics Inc. v. [read post]
10 Jul 2013, 9:15 pm by Patent Docs
By Alison Baldwin -- Just before the July 4th holiday, the Federal Circuit issued its ruling in Fresenius USA, Inc. v. [read post]
29 Sep 2020, 9:50 pm by Patent Docs
The Federal Circuit recently reinforced the primacy of these rubrics in Biogen MA, Inc. v. [read post]
26 Mar 2015, 9:59 pm by Patent Docs
The Federal Circuit's decision in Cadence Pharmaceuticals Inc. v. [read post]
5 Apr 2020, 9:57 pm by Patent Docs
Mylan Pharmaceuticals Inc., the Federal Circuit reversed a decision by the U.S. [read post]
13 Sep 2012, 9:59 pm by Patent Docs
By Andrew Williams -- Last week, the Federal Circuit partially overturned the U.S. [read post]
12 May 2010, 9:59 pm by Patent Docs
Immutopics, Inc., the Federal Circuit affirmed a claim construction decision and corresponding summary judgment of non-infringement rendered by the U.S. [read post]
25 Jan 2012, 9:00 pm by Patent Docs
Cir. 2011), the Federal Circuit released Streck II (Streck, Inc. v. [read post]
10 Apr 2019, 9:59 pm by Patent Docs
Blacklidge Emulsions, Inc., the Federal Circuit affirmed determinations by the U.S. [read post]
19 Aug 2018, 9:59 pm by Patent Docs
Custopharm Inc., the Federal Circuit affirmed a decision by the U.S. [read post]
4 Sep 2012, 9:59 pm by Patent Docs
Noonan -- Last Friday, the Federal Circuit reconsidered en banc the Court's decisions in Akamai Technologies, Inc. v. [read post]
29 Jul 2013, 9:26 pm by Patent Docs
This principle of patent law was reaffirmed by the Federal Circuit last week in Teva Pharmaceuticals USA, Inc. v. [read post]
15 May 2016, 7:04 pm by Consuella Pachico
According to a potential class action filed in a California federal court, Genentech Inc., Roche’s biotechnology subsidiary, has been accused of cheating providers by being dishonest about how much Herceptin, a breast cancer medication, it provides in each multi-dose vial. [read post]